To apparently little effect, Nature Biotechnology has been commenting on the oddly unscientific ways of biotech for 30 years. Revisiting the exasperation and occasional ridicule of this journal’s editorials, this Comment explores how populist and commercial lobbies have sidetracked regulations — in particular, those for genetically modified organisms and biosimilars. In a lesson germane in today’s political climate, re-establishing a rational path rapidly may reduce the damage.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
A broad and inclusive enterprise. Nat. Biotechnol. 14, 235 (1996).
Greer, S. L., Jarman, H., Kulikoff, R. & Yaver, M. Lancet Reg. Health Am. 48, 101173 (2025).
Similarity trials. Nat. Biotechnol. 29, 1 (2011).
Schellekens, H. Nat. Biotechnol. 22, 1357–1359 (2004).
The end of the beginning? Nat. Biotechnol. 24, 367 (2006).
Another nail in the biosimilar coffin? Nat. Biotechnol. 30, 198 (2012).
First US biosimilar launch. Nat. Biotechnol. 33, 1013 (2015).
The INN crowd. Nat. Biotechnol. 31, 1055 (2013).
Chaudhari, K. & Emerton, D. Nat. Rev. Drug Discov. 24, 580–581 (2025).
Niazi. S. K. BioRationality: entering a new era of affordable biosimilar development. https://www.centerforbiosimilars.com/view/biorationality-the-new-era-of-affordable-biosimilar-development (2025).
Quist, D. & Chapela, I. H. Nature 414, 541–543 (2001).
More gods and monsters. Nat. Biotechnol. 17, 207 (1999).
The numerology of idiocy. Nat. Biotechnol. 20, 319 (2002).
The fear factor. Nat. Biotechnol. 20, 957 (2002).
Reburnishing golden rice. Nat. Biotechnol. 23, 395 (2005).
Label without a cause. Nat. Biotechnol. 32, 1169 (2014).
An incredible fudge. Nat. Biotechnol. 34, 997 (2016).
Senior, M. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02994-1 (2026).
FDA. Flexible requirements for cell and gene therapies to advance innovation. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/flexible-requirements-cell-and-gene-therapies-advance-innovation (2026).
FDA. Use of Bayesian methodology in clinical trials of drug and biological products. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products (2026).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Supplementary information
Supplementary Information (download XLSX )
Supplementary Table 1
Rights and permissions
About this article
Cite this article
Hodgson, J. Lessons from biotech’s unscientific evolution. Nat Biotechnol 44, 342–344 (2026). https://doi.org/10.1038/s41587-026-03029-z
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-026-03029-z
